Abstract
Alzheimer's disease, one of the most common causes of dementia, places a significant socioeconomic burden on aging societies. Encouragingly, extensive research on this neurocognitive disorder has finally uncovered the underpinnings of its pathophysiology, igniting a new era of treatment possibilities. Furthermore, the advent of amyloid PET imaging has allowed diagnosis of the amyloid pathology, the underlying cause of Alzheimer's disease. Notwithstanding the initial setback with aducanumab, the subsequent full FDA approval of two anti-amyloid antibody drugs (Lecanemab and Donanemab) has revolutionized the treatment landscape. These disease-modifying drugs are designed to target and remove beta-amyloid. This review covers the updated diagnostic criteria for Alzheimer's disease and discusses recent developments in treatment strategies, including these new disease-modifying drugs.